Research Output
Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose–Response Relationship Using Intracellular Pharmacodynamic Modeling (PDi)
  The human disease tuberculosis (TB) is the leading cause of death from a single infectious agent. A quarter of the world’s population is estimated to be latently infected. Drug development and screening is slow and costly. We have developed a physiologically relevant assay to screen drugs against TB when inside immune cells. This chapter will describe a newly developed preclinical drug screening assay for TB, using high-content imaging and pharmacokinetic/pharmacodynamic modeling.

  • Date:

    12 May 2021

  • Publication Status:

    Published

  • Publisher

    Humana

  • DOI:

    10.1007/978-1-0716-1358-0

  • Funders:

    Medical Research Council

Citation

Donnellan, S., Martínez-Rodríguez, C., Aljayyoussi, G., & Biagini, G. A. (2021). Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose–Response Relationship Using Intracellular Pharmacodynamic Modeling (PDi). In C. Barreiro, & J. Barredo (Eds.), Antimicrobial Therapies: Methods and Protocols (393-408). New York: Humana Press. https://doi.org/10.1007/978-1-0716-1358-0

Authors

Keywords

Tuberculosis, Drug screening, Mycobacteria, Antibiotics, Pharmacokinetic and pharmacodynamic drug Modeling

Monthly Views:

Available Documents